Glaukos

Glaukos shares rose to a record high of $190.27; market capitalization stands at $11.03 billion. In Q2 2026 the company reported revenue of $185.6 million (+49.5% YoY), beating analysts' estimates, after which the full-year revenue guidance was raised. Following the results, several firms raised their price targets, while InvestingPro currently rates the stock as overvalued and 11 analysts revised their earnings estimates upward. The price increase follows a year-to-date gain of 111.6% and underscores positive investor sentiment toward Glaukos' growth prospects in the medtech sector. » Altro su de.investing.com

Glaukos's stock rose to a record high of $184.45, bringing market capitalization to $10.83 billion. In the second quarter of 2026 the medical device company generated $185.6 million in revenue (+50% year‑on‑year) and reported a loss per share that was smaller than expected, after which Glaukos raised its full‑year revenue guidance. Several analysts lifted their price targets, while an InvestingPro analysis classifies the stock at current levels as possibly overvalued. » Altro su de.investing.com

Glaukos reported a 49.54% revenue increase to $185.61 million in the second quarter, significantly beating analysts’ expectations. Management has sharply raised the full-year forecast, prompting heavy accumulation of the stock on high trading volume. The commercial breakthrough of the glaucoma implant iDose TR is viewed as a driver of long-term dynamic growth. » Altro su finanzen.net